Cytosorbents Corp. (CTSO)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 1175151 · fiscal year ends in Dec
Closing price $4.62 on 30 Oct 2026; 52-week range $3.07 to $16.74.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $37.2M
- Revenue growth
- 3.1%
- Net income, last twelve months
- -$18.2M
- Earnings per share
- -$0.29
- Gross margin
- 71.6%
- Operating margin
- -34.7%
- Net margin
- -48.9%
- Free cash flow
- -$9.3M
- Market value
- $290.0M
- Cash
- $4.4M
- Debt
- $17.2M
- Shares outstanding
- 62.8M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $37.1M | -$14.7M | -$8.2M | -$0.13 | -$12.5M | 10-K filed 30 Mar 2026 |
| FY2024 | 31 Dec 2024 | $35.6M | -$16.5M | -$20.7M | -$0.38 | -$14.7M | 10-K filed 31 Mar 2025 |
| FY2023 | 31 Dec 2023 | $31.1M | -$31.9M | -$29.2M | -$0.65 | -$22.2M | 10-K filed 15 Mar 2024 |
| FY2022 | 31 Dec 2022 | $34.7M | -$31.5M | -$32.8M | -$0.75 | -$34.3M | 10-K filed 9 Mar 2023 |
| FY2021 | 31 Dec 2021 | $43.2M | -$22.7M | -$24.6M | -$0.57 | -$17.6M | 10-K filed 10 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $9.6M | -$4.4M | -$0.07 |
| Q1 FY2026 | 31 Mar 2026 | $8.9M | -$5.1M | -$0.08 |
| Q4 FY2025 | 31 Dec 2025 | $9.2M | -$5.5M | -$0.09 |
| Q3 FY2025 | 30 Sep 2025 | $9.5M | -$3.2M | -$0.05 |
| Q2 FY2025 | 30 Jun 2025 | $9.6M | $1.9M | $0.03 |
| Q1 FY2025 | 31 Mar 2025 | $8.7M | -$1.5M | -$0.02 |
| Q4 FY2024 | 31 Dec 2024 | $9.2M | -$7.6M | -$0.14 |
| Q3 FY2024 | 30 Sep 2024 | $8.6M | -$2.8M | -$0.05 |
Company events
The newest 8-K filings of 286 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 23 Sep 2026 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 8 Sep 2026 | 8-K | Bylaws or fiscal year change | 5.03, 9.01 |
| 14 Aug 2026 | 8-K | Shareholder vote | 5.07 |
| 7 Aug 2026 | 8-K | Investor update | 7.01, 9.01 |
| 6 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 6 Jul 2026 | 8-K | Delisting notice | 3.01 |
| 25 Jun 2026 | 8-K | Investor update | 7.01, 9.01 |
| 13 May 2026 | 8-K | Results | 2.02, 9.01 |
| 2 Apr 2026 | 8-K | Delisting notice | 3.01 |
| 25 Mar 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 13 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 3 Oct 2025 | 8-K | Delisting notice | 3.01 |
Every filing
The newest filings with the SEC of 524 held.
| Filed | Form | Period |
|---|---|---|
| 23 Sep 2026 | 8-K | 22 Sep 2026 |
| 8 Sep 2026 | 8-K | 8 Sep 2026 |
| 14 Aug 2026 | 8-K | 13 Aug 2026 |
| 7 Aug 2026 | 8-K | 6 Aug 2026 |
| 6 Aug 2026 | 8-K | 6 Aug 2026 |
| 6 Aug 2026 | 10-Q | 30 Jun 2026 |
| 6 Jul 2026 | 8-K | 29 Jun 2026 |
| 25 Jun 2026 | ARS | 31 Dec 2025 |
| 25 Jun 2026 | DEFA14A | – |
| 25 Jun 2026 | DEF 14A | 13 Aug 2026 |
| 25 Jun 2026 | 8-K | 24 Jun 2026 |
| 11 Jun 2026 | PRE 14A | 11 Jun 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 15 Sep 2026 | Chan Phillip P., Chief Executive Officer | Purchase | 3,774 | $6.00 | $22.6K | 100,996 | 16 Sep 2026 |
| 15 Sep 2026 | Sobel Alan D., Director | Purchase | 1,900 | $6.12 | $11.6K | 9,287 | 16 Sep 2026 |
| 15 Sep 2026 | Sobel Alan D., Director | Purchase | 500 | $6.05 | $3.0K | 9,787 | 16 Sep 2026 |
| 15 Sep 2026 | Sobel Alan D., Director | Purchase | 100 | $6.01 | $601 | 9,887 | 16 Sep 2026 |
| 14 Sep 2026 | Capponi Vincent, President and COO | Purchase | 1,800 | $6.07 | $10.9K | 40,114 | 16 Sep 2026 |
| 14 Sep 2026 | Capponi Vincent, President and COO | Purchase | 273 | $5.90 | $1.6K | 40,387 | 16 Sep 2026 |
| 4 Sep 2026 | Chan Phillip P., Chief Executive Officer | Purchase | 200,000 | $0.35 | $70.0K | 1,944,432 | 9 Sep 2026 |
| 15 Jun 2026 | Mariani Peter J, Chief Financial Officer | Purchase | 100,000 | $0.44 | $44.0K | 638,113 | 16 Jun 2026 |
| 15 Jun 2026 | Chan Phillip P., Chief Executive Officer | Purchase | 10,333 | $0.43 | $4.4K | 1,744,432 | 15 Jun 2026 |
| 12 Jun 2026 | Chan Phillip P., Chief Executive Officer | Purchase | 251,136 | $0.40 | $100.5K | 1,734,099 | 15 Jun 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 13 Feb 2026 | AVENIR CORP | 13G amended | 8.3% | 5.2M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 114.4K | -7.66% | 10.27 |
| 30 Sep 2026 | 123.9K | +2.72% | 11.98 |
| 15 Sep 2026 | 120.6K | -94.77% | 2.65 |
| 31 Aug 2026 | 2.3M | +6.86% | 18.3 |
| 14 Aug 2026 | 2.2M | +0.73% | 29.87 |
| 31 Jul 2026 | 2.1M | +1.12% | 38.34 |
| 15 Jul 2026 | 2.1M | +1.92% | 26.86 |
| 30 Jun 2026 | 2.1M | -0.41% | 6.23 |
Funds that hold it
From each fund's latest Form 13F.
57 funds held it at 30 Jun 2026: 17 added and 12 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Avenir Corp. | 273,117 | $1.9M | -1,398 |
| Neuberger Berman Group LLC | 103,615 | $740.5K | +15,036 |
| Vanguard Capital Management LLC | 100,740 | $715.9K | +1,793 |
| CM Management, LLC | 77,711 | $552.2K | 0 |
| Skylands Capital, LLC | 63,758 | $453.1K | -26,110 |
| BlackRock, Inc. | 33,011 | $234.6K | -8,199 |
| Geode Capital Management, LLC | 31,687 | $225.2K | -5,537 |
| Sargent Investment Group, LLC | 29,250 | $207.9K | +308 |
| Pathstone Holdings, LLC | 26,311 | $187.0K | -2 |
| Vanguard Fiduciary Trust Co. | 16,640 | $118.2K | +122 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $26.3B, market value $110.9B
- 3M Co. (MMM): revenue $25.2B, market value $90.1B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $60.8B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $53.9B
- Medline Inc. (MDLN): revenue –, market value $42.2B
- Resmed Inc. (RMD): revenue $5.7B, market value $32.3B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $30.7B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $28.8B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.1B
- Solventum Corp. (SOLV): revenue $8.3B, market value $13.8B